Group 1: Abatacept at weeks 0, 2, 4 and 8 in combination with Interleukin-2 only for 16 weeks starting at week 0 Group 2 clinical trials

Balancing "bad" and "good" immune cells: testing a novel method for monitoring an immunosuppression strategy in people with Type 1 diabetes

This study is testing a new way to quickly check if treatments for Type 1 diabetes are working. It involves two medicines to help balance immune cells and aims to find better ways to stop the body from attacking insulin-producing cells.